Pregnancy outcomes in myeloproliferative neoplasms: A Mayo Clinic report on 102 pregnancies
暂无分享,去创建一个
A. Tefferi | M. Patnaik | A. Pardanani | N. Gangat | A. Wolanskyj-Spinner | Maansi Joshi | Meera Yogarajah | Sahrish H Shah
[1] D. Neuberg,et al. Pregnancy Outcomes, Risk Factors, and Gestational Cell Count Trends in Pregnant Women with Essential Thrombocythemia and Polycythemia Vera , 2019, Blood.
[2] A. Tefferi,et al. Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger , 2018, American journal of hematology.
[3] S. Bewley,et al. Pregnancy outcomes in myeloproliferative neoplasms: UK prospective cohort study , 2016, British journal of haematology.
[4] M. Cazzola,et al. Impact of mutational status on pregnancy outcome in patients with essential thrombocytemia , 2015, Haematologica.
[5] J. Puetz. Thrombin time and fibrinogen as initial screening tests for people with inherited bleeding disorders , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.
[6] R. Latagliata,et al. Outcome of 122 pregnancies in essential thrombocythemia patients: A report from the Italian registry , 2009, American journal of hematology.
[7] A. Tefferi,et al. Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies , 2009, European journal of haematology.
[8] M. Cazzola,et al. Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation. , 2007, Blood.
[9] Dougald M Monroe,et al. Coagulation 2006: a modern view of hemostasis. , 2007, Hematology/oncology clinics of North America.
[10] G. Rodgers,et al. Comparison of five thrombin time reagents. , 2003, Clinical chemistry.